Vertex cleans up its pipeline; FDA grants priority review to Jakafi for GVHD

→ While AbbVie was stepping up to challenge Vertex on cystic fibrosis today, the Boston-based biotech was engaged in a little pipeline cleanup. Vertex execs say they decided to drop a drug called VX-210 after an independent monitoring committee concluded the Phase IIb was a bust. Vertex bought the drug a few years ago from BioAxone, paying only $10 million upfront and promising up to $90 million more — not something that will break the bank at Vertex.

→ The FDA has promised a faster-than-standard priority review process for Incyte’s $INCY Jakafi as a treatment for acute graft-versus-host-disease (GVHD), that have not responded adequately to corticosteroids, subset of patients that have no other options. The drug is the company’s biggest revenue generator, and is approved to treat a host of diseases, including bone marrow disorder polycythemia vera and myelofibrosis.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Sr. Manager, Regulatory Affairs, CMC
CytomX Therapeutics San Francisco, CA
Marketing Associate - Demand Generation
Catalytic Data Science Charleston, SC
Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco

Visit Endpoints Careers ->